A. Chalian

Papers

1

Total Citations

2

H-Index

1

About

A. Chalian is a leading surgical oncologist whose research centers on the treatment of head and neck cancers, with a particular focus on de-intensification strategies for HPV-related oropharyngeal squamous cell carcinoma. His major contribution lies in pioneering volume- and dose-reduction protocols following transoral robotic surgery (TORS), aiming to preserve quality of life without compromising oncologic outcomes. In his most cited work, a Phase II study published in 2022, Chalian demonstrated that carefully selected patients with p16+ disease can safely undergo reduced adjuvant therapy after TORS and neck dissection, minimizing long-term toxicity. This work, cited 2 times, reflects his commitment to evidence-based surgical de-escalation. Beyond this study, Chalian is recognized for advancing minimally invasive surgical techniques and refining patient selection criteria for organ-preserving approaches. His research has helped shape modern paradigms for managing HPV-positive oropharyngeal cancer, balancing cure rates with functional preservation. As a clinician-scientist, Chalian continues to influence head and neck oncology through clinical trials and surgical innovation.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
A Phase II Study of Volume and Dose De-Intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma
2 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 16

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago